Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755438 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 204
- Enrollment target
NCT05755438 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 204 participants.
The verdict
NCT05755438, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 204 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2025-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755438
The ClinicalTrials.gov registry entry for NCT05755438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT05755438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05755438 about?
NCT05755438 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)". The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
What is the current status of trial NCT05755438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2023-03-10. Estimated completion is 2025-08-13.
What interventions are being tested in trial NCT05755438?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT05755438?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.